Verastem's KRAS G12D Drug Posts Pancreatic Responses, Advances to Phase III

Verastem's KRAS inhibitor shows promise in pancreatic cancer

Verastem Oncology reports encouraging early results for its KRAS G12D inhibitor, which it’s studying in more than 200 patients with advanced solid tumors like metastatic pancreatic ductal adenocarcinoma and non-small…

Verastem (NASDAQ:VSTM) Shares Gap Up - Time to Buy?

Verastem (NASDAQ:VSTM) Shares Gap Up - Still a Buy?

Verastem cancer drug shows early promise in small study

Wall Street analysts believe Verastem’s drug to now be “competitive” in what’s quickly become one of the most active and crowded areas of oncology research.

Verastem Oncology jumps after pricing $250M securities offering (VSTM:NASDAQ)

Verastem Oncology (VSTM) stock jumps 16% as it prices a $250M offering to fund VS-7375 clinical development.

Verastem CEO claims RAS drug has 'set a new benchmark' for tricky cancer in early readout

The Entire Business World on a Single Page with the Web's Most Comprehensive One-Stop Finance News Hub.

Verastem makes its stand as a RevMed competitor in pancreatic cancer

Verastem Oncology had a big Wednesday morning: It announced new data amid a tense competition for the next-wave KRAS agents, as well as a $250 million raise and the departure of its CEO. The Massachusetts ...